Abstract
This patent application discloses a novel class of cyclic peptides, represented by Formula I, designed to selectively trap Interleukin-1β (IL-1β). These peptides offer promising therapeutic potential for slowing the progression of atherosclerotic cardiovascular disease (ASCVD).